← All trials
NCT03236636
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2017
- Primary completion
- Aug 31, 2019
- Completion date
- Aug 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 280
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beijing Shenogen Biomedical Co., LtdLead sponsor
- Anhui Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Chinese Academy of Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesCollaborator
- Hangzhou Normal UniversityCollaborator
- Hebei UniversityCollaborator
- Jilin UniversityCollaborator
- Nantong UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- People's Liberation Army of ChinaOverall official - principal investigator
- Southern Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Sichuan UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Peking UniversityCollaborator
- Capital Medical UniversityCollaborator
- Central South UniversityCollaborator
- Jinan UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Foshan First People's HospitalCollaborator
- Linyi Tumour HospitalCollaborator
- Chifeng Municipal HospitalCollaborator
- Chongqing Medical UniversityCollaborator
- Haikou People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.